Skip to content

Study · Randomized controlled trial · n = 44 · 2017

4 results

L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.

Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z, Akhondzadeh S

Human psychopharmacology8 May 2017Cited by 28 (Europe PMC)

PMID28485008 (opens in a new tab)DOI10.1002/hup.2584 (opens in a new tab)PepBankPUB-28485008
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with OCD, L‑carnosine showed a significant time-by-treatment interaction for total Y-BOCS scores.

    In plain wordsIn patients with OCD, total symptom scores showed different changes over time with carnosine versus placebo, both added to fluvoxamine.

    Peptide
    L-carnosine
    Outcome
    Not applicableTotal Y-BOCS treatment interaction
    Study

    n = 44

    Comparator
    Placebo added to fluvoxamine
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 10 weeksAs given in this study (human).

    Measurements

    Time × Treatment interaction F
    8.66 F statistic
    total Y-BOCS, F(2.10, 88.42), p < 0.001

    Source sentences

    Summary
    General linear model repeated measure showed significant effects for Time × Treatment interaction on total Y-BOCS [F (2.10, 88.42) = 8.66, p < 0.001], obsession [F (1.88, 79.34) = 4.96, p = 0.01] and compulsion [F (1.88, 79.11) = 4.57, p = 0.01].
    2 context sentences
    Summary · context
    Forty-four patients diagnosed with moderate to severe OCD were recruited in a randomized double-blind trial.
    Summary · context
    Patients received either L-carnosine or placebo as adjuvant to fluvoxamine for 10 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with OCD, L‑carnosine showed a significant time-by-treatment interaction for obsession scores.

    In plain wordsIn patients with OCD, obsession scores showed different changes over time with carnosine versus placebo, both added to fluvoxamine.

    Peptide
    L-carnosine
    Outcome
    Not applicableObsession treatment interaction
    Study

    n = 44

    Comparator
    Placebo added to fluvoxamine
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 10 weeksAs given in this study (human).

    Measurements

    Time × Treatment interaction F
    4.96 F statistic
    obsession, F(1.88, 79.34), p = 0.01

    Source sentences

    Summary
    General linear model repeated measure showed significant effects for Time × Treatment interaction on total Y-BOCS [F (2.10, 88.42) = 8.66, p < 0.001], obsession [F (1.88, 79.34) = 4.96, p = 0.01] and compulsion [F (1.88, 79.11) = 4.57, p = 0.01].
    2 context sentences
    Summary · context
    Forty-four patients diagnosed with moderate to severe OCD were recruited in a randomized double-blind trial.
    Summary · context
    Patients received either L-carnosine or placebo as adjuvant to fluvoxamine for 10 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with OCD, L‑carnosine showed a significant time-by-treatment interaction for compulsion scores.

    In plain wordsIn patients with OCD, compulsion scores showed different changes over time with carnosine versus placebo, both added to fluvoxamine.

    Peptide
    L-carnosine
    Outcome
    Not applicableCompulsion treatment interaction
    Study

    n = 44

    Comparator
    Placebo added to fluvoxamine
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 10 weeksAs given in this study (human).

    Measurements

    Time × Treatment interaction F
    4.57 F statistic
    compulsion, F(1.88, 79.11), p = 0.01

    Source sentences

    Summary
    General linear model repeated measure showed significant effects for Time × Treatment interaction on total Y-BOCS [F (2.10, 88.42) = 8.66, p < 0.001], obsession [F (1.88, 79.34) = 4.96, p = 0.01] and compulsion [F (1.88, 79.11) = 4.57, p = 0.01].
    2 context sentences
    Summary · context
    Forty-four patients diagnosed with moderate to severe OCD were recruited in a randomized double-blind trial.
    Summary · context
    Patients received either L-carnosine or placebo as adjuvant to fluvoxamine for 10 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with OCD, Y-BOCS scores decreased more with L‑carnosine plus fluvoxamine than placebo plus fluvoxamine.

    In plain wordsIn patients with OCD, carnosine added to fluvoxamine reduced symptoms more than placebo added to fluvoxamine.

    Peptide
    L-carnosine
    Outcome
    DecreaseY-BOCS change at week 10
    Study

    n = 44

    Comparator
    Placebo added to fluvoxamine
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · 10 weeksAs given in this study (human).

    Measurements

    Y-BOCS change
    8.86 points
    L-carnosine
    Y-BOCS change
    5.86 points
    placebo

    Source sentences

    Summary
    At week 10, the change from baseline in Y-BOCS scores was 8.86 ± 2.89 (mean ± SD) in the L-carnosine group compared to 5.86 ± 2.88 in the placebo group.
    3 context sentences
    Summary · context
    L-carnosine results in significant reduction of obsessive-compulsive symptoms when used as an adjuvant to fluvoxamine.
    Summary · context
    Forty-four patients diagnosed with moderate to severe OCD were recruited in a randomized double-blind trial.
    Summary · context
    Patients received either L-carnosine or placebo as adjuvant to fluvoxamine for 10 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.